Extra treatment after surgery for triple-negative breast cancer
Treatments studied
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 74.
- You have been diagnosed with stage II to IIIc triple-negative breast cancer.
- You completed the standard full course of chemotherapy plus immunotherapy before surgery.
- After surgery, there is still cancer in the breast or nearby lymph nodes.
- Your overall health is good (able to do daily activities, no severe heart or kidney problems).
- You are not pregnant or breastfeeding, and agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
Hear when a new Newly Diagnosed Triple-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.